Fibroblast growth factor-21 predicts adverse outcome in community-acquired pneumonia

2018 ◽  
Author(s):  
Fahim Ebrahimi ◽  
Carole Wolffenbuttel ◽  
Claudine A Blum ◽  
Beat Muller ◽  
Philipp Schuetz ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Adverse Outcome ◽  
Community Acquired Pneumonia ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth

scholarly journals Fibroblast growth factor 21 predicts outcome in community-acquired pneumonia: secondary analysis of two randomised controlled trials

2018 ◽  
Vol 53 (2) ◽  
pp. 1800973 ◽  
Author(s):  
Fahim Ebrahimi ◽  
Carole Wolffenbuttel ◽  
Claudine A. Blum ◽  
Christine Baumgartner ◽  
Beat Mueller ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Randomised Controlled Trials ◽  
Secondary Analysis ◽  
Community Acquired Pneumonia ◽  
Fibroblast Growth Factor 21 ◽  
Controlled Trials ◽  
Fibroblast Growth ◽  
Randomised Controlled ◽  
Clinical Stability

Acute systemic inflammatory conditions are accompanied by profound alterations of metabolism. However, the role of fibroblast growth factor 21 (FGF21), a recently identified central regulator of metabolism, is largely unknown in community-acquired pneumonia (CAP). This study aims to characterise the pattern of FGF21 in pneumonia and associations with disease severity and outcome.This is a secondary analysis of two independent multicentre randomised controlled trials in patients presenting to the emergency department with CAP. Primary and secondary efficacy parameters included 30-day mortality, length of hospital stay, time to clinical stability and duration of antibiotic treatment.A total of 509 patients were included in the analysis. FGF21 levels at admission strongly correlated with disease severity, as measured by the Pneumonia Severity Index. Increased levels of FGF21 were associated with prolonged time to clinical stability, antibiotic treatment and hospitalisation. FGF21 levels at admission were significantly higher in nonsurvivors than in survivors, yielding a 1.61-fold increased adjusted odds ratio of 30-day mortality (95% CI 1.21–2.14; p=0.001). Moreover, FGF21 was found to identify patients for 30-day mortality with superior discriminative power compared with routine diagnostic markers.Moderate-to-severe CAP patients with higher levels of FGF21 were at increased risk for clinical instability, prolonged hospitalisation and 30-day all-cause mortality.

Effects of anti-inflammatory treatment on fibroblast growth factor-21 in obesity and metabolic syndrome

2019 ◽  
Author(s):  
Fahim Ebrahimi ◽  
Sandrine Urwyler ◽  
Matthias Betz ◽  
Emanuel Christ ◽  
Philipp Schuetz ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Anti Inflammatory

Fibroblast growth factor 21 (FGF21) in hyper- and hypothyroidism, association with metabolic disturbances

2020 ◽  
Author(s):  
Ewa Szczepańska ◽  
Małgorzata Gietka-Czernel ◽  
Piotr Glinicki ◽  
Helena Jastrzębska ◽  
Jadwiga Słowińska-Srzednicka ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Metabolic Disturbances
Sign in / Sign up

Export Citation Format

Share Document